Rein Therapeutics (NASDAQ:RNTX) Shares Up 1.6% – Should You Buy?

Rein Therapeutics Inc. (NASDAQ:RNTX)’s stock price was up 1.6% during mid-day trading on Friday . The company traded as high as $1.3451 and last traded at $1.30. Approximately 44,298 shares changed hands during mid-day trading, a decline of 51% from the average daily volume of 90,560 shares. The stock had previously closed at $1.28.

Analyst Ratings Changes

Several research analysts recently commented on RNTX shares. Citigroup cut Rein Therapeutics to a “hold” rating in a research note on Wednesday, January 21st. Wall Street Zen cut Rein Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, December 14th. Brookline Capital Acquisition downgraded Rein Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 21st. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Rein Therapeutics in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $8.00.

Rein Therapeutics Trading Up 1.6%

The stock has a market capitalization of $34.17 million, a price-to-earnings ratio of -0.49 and a beta of 1.51. The company’s 50 day moving average is $1.23 and its 200 day moving average is $1.29.

Institutional Trading of Rein Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Gagnon Securities LLC lifted its holdings in shares of Rein Therapeutics by 5.0% in the 4th quarter. Gagnon Securities LLC now owns 240,220 shares of the company’s stock valued at $279,000 after purchasing an additional 11,528 shares during the last quarter. Gleason Group Inc. purchased a new position in Rein Therapeutics during the 3rd quarter worth approximately $26,000. Meridian Wealth Advisors LLC acquired a new position in Rein Therapeutics during the second quarter worth approximately $40,000. Susquehanna International Group LLP acquired a new position in Rein Therapeutics during the third quarter worth approximately $35,000. Finally, HRT Financial LP purchased a new stake in Rein Therapeutics in the fourth quarter valued at approximately $38,000. Institutional investors and hedge funds own 90.89% of the company’s stock.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.